Article ID,Publication Year,Reference,US$/QALY *,Ratio Description,PubMed ID,Target Population,Intervention Description,Title,Comparator Description,Impact
2020-01-34542,2020,Briones 2020 BMC Health Serv Res,13000,carbetocin (cesarean section) VERSUS Standard/Usual Care- 10 IU oxytocin IN Specific disease- postpartum hemorrhage; Age- Adult; Gender- Female; Country- Philippines; Other- cesarean section.,33106169,Specific disease- postpartum hemorrhage; Age- Adult; Gender- Female; Country- Philippines; Other- cesarean section.,carbetocin (cesarean section),Economic evaluation of carbetocin as prophylaxis for postpartum hemorrhage in the  Philippines.,Standard/Usual Care- 10 IU oxytocin,NE
2020-01-34542,2020,Briones 2020 BMC Health Serv Res,44000,carbetocin (vaginal delivery) VERSUS Standard/Usual Care- 10 IU oxytocin IN Specific disease- postpartum hemorrhage; Age- Adult; Gender- Female; Country- Philippines; Other- vaginal delivery.,33106169,Specific disease- postpartum hemorrhage; Age- Adult; Gender- Female; Country- Philippines; Other- vaginal delivery.,carbetocin (vaginal delivery),Economic evaluation of carbetocin as prophylaxis for postpartum hemorrhage in the  Philippines.,Standard/Usual Care- 10 IU oxytocin,NE
2020-01-33559,2020,Quiambao 2020 Int. J. Infect. Dis.,420,rabies pre-exposure prophylaxis immunization+ post-exposure prophylaxis immunization VERSUS Standard/Usual Care- rabies post-exposure prophylaxis immunization IN Healthy; Age- 0 to 18 years; Gender- Both; Country- Philippines.,0,Healthy; Age- 0 to 18 years; Gender- Both; Country- Philippines.,rabies pre-exposure prophylaxis immunization+ post-exposure prophylaxis immunization,Health economic assessment of a rabies pre-exposure prophylaxis program compared with post-exposure prophylaxis alone in high-risk age groups in the Philippines.,Standard/Usual Care- rabies post-exposure prophylaxis immunization,NE
2020-01-33559,2020,Quiambao 2020 Int. J. Infect. Dis.,820,rabies pre-exposure prophylaxis immunization + post-exposure prophylaxis immunization VERSUS Standard/Usual Care- rabies post-exposure prophylaxis immunization IN Healthy; Age- 0 to 18 years; Gender- Both; Country- Philippines.,0,Healthy; Age- 0 to 18 years; Gender- Both; Country- Philippines.,rabies pre-exposure prophylaxis immunization + post-exposure prophylaxis immunization,Health economic assessment of a rabies pre-exposure prophylaxis program compared with post-exposure prophylaxis alone in high-risk age groups in the Philippines.,Standard/Usual Care- rabies post-exposure prophylaxis immunization,NE
2019-01-30896,2019,Avancena 2019 BMJ Open,570,"doctors to the barrios program VERSUS None IN Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Philippines.",31888937,"Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Philippines.",doctors to the barrios program,Cost-effectiveness analysis of a physician deployment program to improve access to healthcare in rural and underserved areas in the Philippines.,None,NE
2015-01-17758,2015,Haasis 2015 PLoS One,1400,Pneumococcal Conjugate Vaccines 13 VERSUS None IN Healthy; Age- 0 to 18 years; Gender- Both; Country- Philippines; Other- infants (universal coverage).,26131961,Healthy; Age- 0 to 18 years; Gender- Both; Country- Philippines; Other- infants (universal coverage).,Pneumococcal Conjugate Vaccines 13,Do Pneumococcal Conjugate Vaccines Represent Good Value for Money in a Lower-Middle Income Country? A Cost-Utility Analysis in the Philippines.,None,NE
2015-01-17758,2015,Haasis 2015 PLoS One,1800,Pneumococcal Conjugate Vaccines 10 VERSUS Standard/Usual Care IN Healthy; Age- 0 to 18 years; Gender- Both; Country- Philippines; Other- infants (universal coverage).,26131961,Healthy; Age- 0 to 18 years; Gender- Both; Country- Philippines; Other- infants (universal coverage).,Pneumococcal Conjugate Vaccines 10,Do Pneumococcal Conjugate Vaccines Represent Good Value for Money in a Lower-Middle Income Country? A Cost-Utility Analysis in the Philippines.,Standard/Usual Care,NE
2015-01-17758,2015,Haasis 2015 PLoS One,2200,Pneumococcal Conjugate Vaccines 13 VERSUS None IN Healthy; Age- 0 to 18 years; Gender- Both; Country- Philippines; Other- Infants (without herd protection).,26131961,Healthy; Age- 0 to 18 years; Gender- Both; Country- Philippines; Other- Infants (without herd protection).,Pneumococcal Conjugate Vaccines 13,Do Pneumococcal Conjugate Vaccines Represent Good Value for Money in a Lower-Middle Income Country? A Cost-Utility Analysis in the Philippines.,None,NE
2015-01-17758,2015,Haasis 2015 PLoS One,3000,Pneumococcal Conjugate Vaccines 10 VERSUS None IN Healthy; Age- 0 to 18 years; Gender- Both; Country- Philippines; Other- Infants (without herd protection).,26131961,Healthy; Age- 0 to 18 years; Gender- Both; Country- Philippines; Other- Infants (without herd protection).,Pneumococcal Conjugate Vaccines 10,Do Pneumococcal Conjugate Vaccines Represent Good Value for Money in a Lower-Middle Income Country? A Cost-Utility Analysis in the Philippines.,None,NE
2015-01-17758,2015,Haasis 2015 PLoS One,410,Pneumococcal Conjugate Vaccines 13 VERSUS Pneumococcal Conjugate Vaccines 10 IN Healthy; Age- 0 to 18 years; Gender- Both; Country- Philippines; Other- Infants (universal coverage).,26131961,Healthy; Age- 0 to 18 years; Gender- Both; Country- Philippines; Other- Infants (universal coverage).,Pneumococcal Conjugate Vaccines 13,Do Pneumococcal Conjugate Vaccines Represent Good Value for Money in a Lower-Middle Income Country? A Cost-Utility Analysis in the Philippines.,Pneumococcal Conjugate Vaccines 10,NE
2015-01-17758,2015,Haasis 2015 PLoS One,620,Pneumococcal Conjugate Vaccines 13 VERSUS Pneumococcal Conjugate Vaccines 10 IN Healthy; Age- 0 to 18 years; Gender- Both; Country- Philippines; Other- Infants (without herd protection).,26131961,Healthy; Age- 0 to 18 years; Gender- Both; Country- Philippines; Other- Infants (without herd protection).,Pneumococcal Conjugate Vaccines 13,Do Pneumococcal Conjugate Vaccines Represent Good Value for Money in a Lower-Middle Income Country? A Cost-Utility Analysis in the Philippines.,Pneumococcal Conjugate Vaccines 10,NE
2015-01-17555,2015,Guerrero 2015 BMC Public Health,Cost-Saving,"Visual inspection with acetic acid (VIA) VERSUS Pap smear at 8 % coverage for women aged 35-55 years old at 5-year intervals IN Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- Philippines.",26223975,"Healthy; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Female; Country- Philippines.",Visual inspection with acetic acid (VIA),A cost-utility analysis of cervical cancer screening and human papillomavirus vaccination in the Philippines.,Pap smear at 8 % coverage for women aged 35-55 years old at 5-year intervals,SE
2002-01-01171,2002,Khan 2002 N Engl J Med,1900,Tuberculin skin testing and treatment with rifampin and pyrazinamide daily for 2 months for positive test results VERSUS Tuberculin skin testing and treatment with isoniazid and pyridoxine daily for 9 months for positive test results IN Documented immigrants 18 years of age or older who entered the US from developing nations (China) int he year 2000,12466510,Documented immigrants 18 years of age or older who entered the US from developing nations (China) int he year 2000,Tuberculin skin testing and treatment with rifampin and pyrazinamide daily for 2 months for positive test results,Global drug-resistance patterns and the management of latent tuberculosis infection in immigrants to the United States,Tuberculin skin testing and treatment with isoniazid and pyridoxine daily for 9 months for positive test results,NE
2002-01-01171,2002,Khan 2002 N Engl J Med,21000,Tuberculin skin testing and treatment with rifampin daily for 4 months for positive test results VERSUS Tuberculin skin testing and treatment with isoniazid and pyridoxine daily for 9 months for positive test results IN Documented immigrants 18 years of age or older who enetered the US from developing nations (China) n the year 2000,12466510,Documented immigrants 18 years of age or older who enetered the US from developing nations (China) n the year 2000,Tuberculin skin testing and treatment with rifampin daily for 4 months for positive test results,Global drug-resistance patterns and the management of latent tuberculosis infection in immigrants to the United States,Tuberculin skin testing and treatment with isoniazid and pyridoxine daily for 9 months for positive test results,NE
2002-01-01171,2002,Khan 2002 N Engl J Med,Cost-Saving,Tuberculin skin testing and treatment with isoniazid and pyridoxine daily for 9 months for positive test results VERSUS No treatment IN Documented immigrants 18 years of age or older who enetered the US from developing nations (China) n the year 2000,12466510,Documented immigrants 18 years of age or older who enetered the US from developing nations (China) n the year 2000,Tuberculin skin testing and treatment with isoniazid and pyridoxine daily for 9 months for positive test results,Global drug-resistance patterns and the management of latent tuberculosis infection in immigrants to the United States,No treatment,SE
1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
